

Novel tools to study the fibrotic stroma

Session	Chair	Title
<b>Cell-ECM interactions I</b>	<b>C. McCulloch</b>	
1. Donald Gullberg, Bergen	8.30-9.10	Integrin $\alpha 1 \beta 1$ - a fibroblast protein with a role in fibrosis
2. Ritva Heljasvaara, Oulu	9.15-9.55	Of mice, men and clouds - new target molecules in the tumor ECM
Coffee	10.00-10.20	
<b>Cell-ECM interactions II</b>	<b>V. Weaver</b>	
3. Christopher McCulloch, Toronto	10.20-11.00	Role of Flightless in Remodeling of the Fibrotic Stroma
4. John Marshall, Barts Cancer Institute	11.05-11.45	The role of integrins in regulation of the stroma
5. Sergey Plotnikov, Toronto	11.50 -12.30	Calcium Sparks in Focal Adhesions Drive Cell Migration Along ECM Stiffness Gradients
Lunch	12.30-13.10	
<b>Mechanism of fibrosis I</b>	<b>R. Heljasvaara</b>	
6. Geir Christensen, Oslo	13.10-13.50	Myocardial fibrosis in heart failure: mechanisms and functional consequences
7. Andreas Romaine, Oslo	13.55-14.25	Syndecan-4 and Integrins: key regulators of the cardiac fibrotic response to pressure overload
8. Mari Elen Strand, Oslo	14.30-15.00	Heparanase: a novel regulator of cardiac inflammation and fibrosis?
Coffee	15.05-15.25	
<b>Tumor stroma associated fibrosis I</b>	<b>D.Gullberg</b>	
9. Arne Östman, KI	15.25-16.05	Clinically relevant marker- and pathway-defined subsets of cancer-associated fibroblasts
10. Agnes Noel, Liege	16.10-16.50	Alpha 11 integrin interacts with PDGFRbeta receptor in pro-invasive breast cancer-associated fibroblasts
11. Jason Northey, UCSF	16.55-17.10	Matrix stiffness and breast cancer risk.
Business meeting SIU	17.15- 17.45	
Dinner	19.30	
<b>Mechanism of fibrosis II</b>	<b>R. Navab</b>	
12. Reetta Hinttala, Oulu	8.30-9.10	Dysfunction of human NHLRC2 as a cause of fibrosis, neurodegeneration and cerebral angiomas (FINCA).
13. Valerie Weaver, UCSF	9.15-9.55	Reciprocal interplay between tumor immunity and fibrosis
Coffee	10.00-10.20	
<b>Tumor stroma associated fibrosis II</b>	<b>A. Östman</b>	
14. Kristian Pietras, Lund, Sweden	10.20-10.50	Microenvironmental control of malignant phenotypes
15. Daniel Öhlund, Umeå, Sweden	10.55-11.30	Deciphering the extracellular matrix composition in pancreatic cancer
16. Roya Navab, Toronto	11.35-12.15	The lysyl oxidase like-1 promotes non-small cell lung cancer tumorigenicity through increased matrix re-organization
Lunch	12.20 -13.00	
<b>Emerging anti-fibrotic therapies</b>	<b>M. Fabre</b>	
17. Christian Klein, Roche Pharmaceutical Research, Switzerland	13.00-13.40	Targeting the fibroblast activation protein (FAP) in the tumor stroma for cancer immunotherapy
18. Myriam Fabre, Oncomatryx Biopharma, Spain	13.45-14.25	Tumor microenvironment-targeted biologics for cancer treatment
Coffee	14.30-14.45	
19. Wolfgang Jarolimek, Pharmaxis, Australia	14.45-15.25	Efficacy of pan- and selective lysyl oxidase inhibitors in reducing fibrosis
Discussion	15.25-16.00	

May 23th

May 24th